Consulting firm Charles River Associates has bolstered its American Life Sciences practice with Andrew Parece and Alex Silver. Parece joins the firm as a Vice-President from Analysis Group, while Silver, who has been appointed a Principal, relocates from China, where he most recently served Crosswave.
Founded in 1965, Charles River Associates (CRA) is one of the larger consulting firms of the globe. The Boston-headquartered advisory has 20 offices internationally, including seven in Europe. The firm supports clients with among others economic, financial, and management consulting services.
Last week CRA unveiled that it has added two high-profile advisors to its US Life Sciences practice: Andrew Parece and Alex Silver. Parece has more than 30 years of consulting experience. Prior to re-joining Charles River Associates, he was a Senior Advisor as well as a Managing Principal at Analysis Group, a North American consultancy with 10 offices across the continent. His work in pharmaceuticals has focused on brand/franchise strategy, pricing, contracting, and market access. Parece, who has been appointed a Vice-President based in Boston, holds an MBA from the Johnson Graduate School of Management at Cornell University and a BA degree in Economics and Computer Science from Cornell University.
Silver specialises in researching target sectors, creating financial and operational analyses, developing business cases, and preparing business plans and model operations for life sciences companies. Most recently, he has been working in China advising global pharmaceutical and healthcare firms. His consulting experience includes brand strategy, commercial and retail sales force management, consumer and trade marketing, and growth and investment strategies. Prior to joining CRA, Silver was a member of the business development team at Crosswave in Shanghai, where he managed early stage life science ventures. Prior to that, he worked for the Chinese operations of among others Bausch + Lomb, Abbott Diabetes Care and Merck. Silver holds an MBA in Finance and Marketing from the Columbia University Graduate School of Business and a BA degree in Philosophy from McGill University.
Commenting on Parece’s return to his roots, Paul Maleh, President and Chief Executive Officer of CRA, says it is “a pleasure to welcome him back,” adding “his consulting experience in such areas as pricing strategy, new product launches, and market research further strengthens CRA’s life sciences offering.”
Greg Bell, Global Practice Leader of CRA’s Life Sciences unit, says: “We’re excited to welcome Andy and Alex. Their expertise bolsters our strategy consulting capabilities to assist life science clients with achieving competitive advantage and optimal performance. We are particularly pleased to see continuing growth in our R&D strategy capabilities.”
Earlier this Joanna Tsai, and expert in antitrust and competition economics, also re-joined CRA as a Vice President in Washington, DC., after a two year stint with the Federal Trade Commission.